Respiratory medicine最新文献

{"title":"Corrigendum to \"Evaluation of radiological lung pattern and disease progression in patients with asbestosis compared to patients with idiopathic pulmonary fibrosis\" [Respir. Med. 262, (2026)].","authors":"Chiara Romei, Leonardo Colligiani, Bianca Cosci, Annalisa De Liperi, Vincenzo Uggenti, Federica Volpi, Roberto Castellana, Laura Tavanti, Francesco Pistelli, Brian Bartholomai, Emanuele Neri, Giovanni Guglielmi","doi":"10.1016/j.rmed.2026.109155","DOIUrl":"https://doi.org/10.1016/j.rmed.2026.109155","url":null,"abstract":"","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":" ","pages":"109155"},"PeriodicalIF":3.3,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148978017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Adherence to inhaled treatment is associated with better disease control and quality of life in mild-to-moderate asthma\" [Respir. Med. 262, (2026), 109127].","authors":"Nicola Scichilone, Giulia Genduso, Diego Bagnasco, Alessandro Barone, Salvatore Battaglia, Alida Benfante, Benedetta Bondi, Matteo Bonini, Luisa Brussino, Giovanna Elisiana Carpagnano, Cristiano Caruso, Francesca Cefaloni, Miriam De Francesco, Stefano Del Giacco, Alessandro Farsi, Sebastian Ferri, Laura Franceschini, Manuela Latorre, Francesca Puggioni, Vitaliano Nicola Quaranta, Erminia Ridolo, Pierachille Santus, Fabio Selvi, Paolo Serra, Antonio Spanevello, Alessandra Tomasello, Martina Zappa, Francesco Blasi, Pierluigi Paggiaro, Giorgio Walter Canonica, Fulvio Braido","doi":"10.1016/j.rmed.2026.109153","DOIUrl":"https://doi.org/10.1016/j.rmed.2026.109153","url":null,"abstract":"","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":" ","pages":"109153"},"PeriodicalIF":3.3,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148930930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Association of the C-reactive protein-triglyceride-glucose (CTI) index with asthma prevalence: Evidence from dual national cohorts\" [Respir. Med. 261 (2026) 109037].","authors":"Wenxuan Zhang, Liya Li, Shuting Du, Yaping Wang, Yuxiang Cao, Chengyun Hu, Jing Wang, Bing Gao","doi":"10.1016/j.rmed.2026.109058","DOIUrl":"10.1016/j.rmed.2026.109058","url":null,"abstract":"","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":" ","pages":"109058"},"PeriodicalIF":3.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148607090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Healthcare professionals' awareness and practice regarding the environmental impact of inhalers: A scoping review.","authors":"Yasir Alhazmi, Philip Chi Lip Kwok, Hoang Anh Tu, Khawaja Husnain Haider, Bandana Saini","doi":"10.1016/j.rmed.2026.109069","DOIUrl":"10.1016/j.rmed.2026.109069","url":null,"abstract":"<p><strong>Background: </strong>Inhalers are essential for managing respiratory diseases but pose an environmental impact, especially those containing propellants, which are potent greenhouse gases. Healthcare professionals can reduce the environmental impact of inhalers through best practice management of respiratory conditions, prescribing non-propellant-containing or lower carbon footprint inhalers and providing consumer education on appropriate use and disposal. However, little is known about the roles of health professionals in sustainable respiratory care. Therefore, this study aimed to source, analyse, and report research concerning healthcare professionals' understanding of the environmental impact of inhalers and their current practices.</p><p><strong>Methods: </strong>A scoping review was conducted using JBI methodology and PRISMA-ScR guidelines to capture diverse study designs across health professions. A strategic search strategy of four databases yielded 693 articles. Articles were screened in two steps (Titles/abstracts and full-text), and relevant articles were reviewed, data extracted and then meaningfully collated into themes.</p><p><strong>Results: </strong>Thirteen studies met the inclusion criteria and involved surveys, interviews or interventions conducted with health professionals. Key themes included awareness and attitudes toward inhalers' environmental impact, factors influencing prescribing and disposal practice, impact of interventions and the requirements for sustainability education.</p><p><strong>Conclusion: </strong>This review demonstrated significant gaps in healthcare professionals' awareness and practices regarding the environmental impact of inhalers. These results highlight the need for educational and stewardship programmes to enhance healthcare professionals' understanding and reduce the environmental impact of inhalers.</p>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":" ","pages":"109069"},"PeriodicalIF":3.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148621349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rheumatoid arthritis-associated interstitial lung disease: Pathogenesis, risk stratification, and management.","authors":"Rong Gao, Siyan Liu, Lixian Song","doi":"10.1016/j.rmed.2026.109066","DOIUrl":"10.1016/j.rmed.2026.109066","url":null,"abstract":"<p><p>Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is one of the most clinically significant extra-articular manifestations of rheumatoid arthritis and an important cause of morbidity and premature mortality. Its clinical spectrum ranges from asymptomatic radiographic abnormalities to rapidly progressive fibrosing lung disease with respiratory failure. Current evidence indicates that RA-ILD is biologically heterogeneous and arises from the interplay of mucosal autoimmunity, genetic susceptibility, epithelial injury, dysregulated innate and adaptive immune responses, and aberrant tissue repair. This heterogeneity has important implications for diagnosis, prognosis, and treatment selection. High-resolution computed tomography remains central to disease detection and radiologic phenotyping, while pulmonary function testing, serologic profiling, circulating biomarkers, and multidisciplinary discussion improve risk stratification and longitudinal assessment. Management should integrate the relative contribution of inflammation and fibrosis with current conditional guideline recommendations, and may include short-term glucocorticoids, conventional immunosuppressants, biologic or targeted synthetic disease-modifying antirheumatic drugs, antifibrotic therapy for documented progressive pulmonary fibrosis, and evaluation for pulmonary hypertension-associated ILD in advanced disease. However, clinical decision-making remains limited by the scarcity of randomized RA-ILD-specific trials, the lack of standardized definitions of disease progression, and uncertainty regarding optimal treatment sequencing. This review summarizes current understanding of the pathogenesis, risk factors, diagnostic evaluation, treatment strategies, and prognostic determinants of RA-ILD, with emphasis on phenotype-oriented management and practical issues relevant to respiratory and multidisciplinary care.</p>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":" ","pages":"109066"},"PeriodicalIF":3.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148607023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"De-escalation of inhaled corticosteroids and other maintenance asthma therapies in dupilumab-treated patients with severe asthma: a real-world study.","authors":"Matteo Bonato, Elisabetta Favero, Michele Ciresi, Elisabetta Marcon, Francesca Savoia, Anna Talia Gaccione, Matteo Dalla Libera, Martina Turrin, Marco Stellin, Massimo Sonego, Enzo Emanuelli, Marco Caminati, Gianenrico Senna, Micaela Romagnoli","doi":"10.1016/j.rmed.2026.109076","DOIUrl":"10.1016/j.rmed.2026.109076","url":null,"abstract":"<p><strong>Background: </strong>Biologic therapies for severe T2-high asthma demonstrated oral corticosteroid-sparing effects, but evidence on the harmlessness of de-escalating inhaled corticosteroids and other in patients controlled with dupilumab remains limited.</p><p><strong>Objective: </strong>To evaluate, in a real-world setting, the clinical impact of de-escalating high-dose ICS, LAMA and LTRA in patients with severe asthma controlled with dupilumab.</p><p><strong>Methods: </strong>We conducted a retrospective bicentric observational study including 54 patients with severe asthma who initiated dupilumab between January 2022 and December 2023. Changes in maintenance therapy during the first year were classified as de-escalation, continuation, or never treated. Primary outcomes at 18 months included ACT score, acute exacerbation rate (AER), FEV₁, their variation from baseline, chronic OCS use and clinical remission.</p><p><strong>Results: </strong>Dupilumab significantly improved asthma control, lung function, AER, and OCS use. The proportion of patients receiving high-dose ICS decreased from 85.1% at baseline to 47.1% at 18 months (p < 0.001). Similar trends for LAMA and LTRA. Primary outcomes at 18 months did not differ significantly between patients who de-escalated maintenance therapy and those who continued treatment. Clinical remission was achieved in 53.7% of patients at 12 months and 63.4% at 18 months. Maintenance therapy de-escalation did not affect the likelihood of achieving clinical remission, although nearly half of patients in remission remained on low-to-medium dose ICS.</p><p><strong>Conclusions: </strong>In patients with severe asthma controlled with dupilumab, de-escalation of high-dose ICS, LAMA, or LTRA was not associated with clinical deterioration and did not preclude achievement of clinical remission.</p>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":" ","pages":"109076"},"PeriodicalIF":3.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148670556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between urinary metabolites of volatile organic compounds and lung function: A cross-sectional study","authors":"Jian Chen ,&nbsp;Yan Li ,&nbsp;Zhenzong Han ,&nbsp;Jixiang Liu ,&nbsp;Lin Hou","doi":"10.1016/j.rmed.2026.108683","DOIUrl":"10.1016/j.rmed.2026.108683","url":null,"abstract":"<div><h3>Background</h3><div>Volatile organic compounds (VOCs), play a major role in exacerbating air pollution and present a threat to human health. However, the association between specific VOCs and lung function in the general population has not been extensively explored.</div></div><div><h3>Objectives</h3><div>Our study aimed to examine the correlation between urinary VOC metabolites (mVOCs) concentrations and lung function, among a typical sample of the adult population.</div></div><div><h3>Methods</h3><div>The correlation between urinary mVOCs and lung function was analyzed using logistic regression models, QG-C, WQS, and BKMR models were employed.</div></div><div><h3>Results</h3><div>Our study revealed that higher concentrations of certain urinary mVOCs significantly correlated with an increased risk of abnormal lung function, especially URXAMC and URXDHB. A significant nonlinear correlation was observed between URXDHB and FEV1 % pred &lt;80 % (<em>P</em> for overall &lt;0.001, <em>P</em> for nonlinear &lt;0.001), and a nonlinear correlation was noted between URXAMC and the incidence of FEV1 % pred &lt;80 % (<em>P</em> for overall, <em>P</em> for nonlinear = 0.012).</div></div><div><h3>Conclusion</h3><div>VOCs exposure is associated with compromised lung health, and particularly strong correlations exist between URXAMC/URXDHB and abnormal lung function; These findings provide new insights for respiratory disease prevention and control.</div></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"253 ","pages":"Article 108683"},"PeriodicalIF":3.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146093896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative effectiveness and safety of novel antidiabetic agents in the management of obstructive sleep apnea: a systematic review, meta-analysis, and network meta-analysis","authors":"Ying-tian Yang ,&nbsp;Xin-zheng Hou ,&nbsp;Xi-rui Zhang ,&nbsp;Zhen-peng Zhang ,&nbsp;Shi-han Wang","doi":"10.1016/j.rmed.2026.108671","DOIUrl":"10.1016/j.rmed.2026.108671","url":null,"abstract":"<div><h3>Background</h3><div>Obstructive sleep apnea (OSA) is a prevalent but frequently underdiagnosed type of sleep-disordered breathing. Excessive obesity is a primary reversible risk factor for OSA. A range of novel antidiabetic agents has recently demonstrated promising potential for improving OSA severity through weight loss and metabolic regulation.</div></div><div><h3>Objective</h3><div>This study aimed to examine the effectiveness and safety of novel antidiabetic agents for people with OSA.</div></div><div><h3>Methods</h3><div>We searched PubMed, Web of Science, Cochrane Library, and Embase database from inception to May 18, 2025. Pairwise meta-analysis and Bayesian network meta-analysis (NMA) were conducted to compare relative efficacy.</div></div><div><h3>Results</h3><div>A total of 8 RCTs and 2 non-RCTs involving 1280 OSA participants were enrolled. Compared with the control group, SGLT-2i (MD = −7.73 events/h, 95 % CI [-9.83, −5.64]), GLP-1 RAs (MD = −5.19 events/h, 95 % CI [-6.87, −3.51]), and tirzepatide (−21.89 events/h, 95 % CI [-26.01, −17.77]) could significantly decrease AHI. The NMA results suggested that tirzepatide ranking highest of producing the greatest AHI reduction (MD = −21.85 events/h, 95 % CI [−27.52, −16.34]), along with the most substantial decreases in body weight (MD = −19.41 kg, 95 % CI [-21.00, −17.82]) and blood pressure (MD_SBP = −5.86 mmHg, 95 % CI [-7.97, −3.74]; MD_DBP = −1.96 mmHg, 95 % CI [-3.45, −0.46]).</div></div><div><h3>Conclusion</h3><div>Based on indirect evidence, tirzepatide was associated with the largest estimated magnitude of AHI reduction, presumably mediated by its weight-loss effects. For obesity-related OSA patients intolerant to continuous positive airway pressure therapy, tirzepatide may represent a potential adjunctive or alternative pharmacological option. High-quality studies are still needed to validate these findings further.</div></div><div><h3>Prospero registration number</h3><div>CRD420251165267.</div></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"253 ","pages":"Article 108671"},"PeriodicalIF":3.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146093931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adaptive support ventilation with IntelliSync versus pressure support ventilation for non-invasive ventilation in acute exacerbation of COPD: A feasibility randomized trial","authors":"Selva Vijay,&nbsp;Inderpaul Singh Sehgal,&nbsp;Ritesh Agarwal,&nbsp;Valliappan Muthu,&nbsp;Sahajal Dhooria,&nbsp;Kuruswamy Thurai Prasad,&nbsp;Ashutosh Nath Aggarwal","doi":"10.1016/j.rmed.2026.108690","DOIUrl":"10.1016/j.rmed.2026.108690","url":null,"abstract":"<div><h3>Background</h3><div>While non-invasive ventilation (NIV) is recommended for managing acute exacerbations of chronic obstructive pulmonary disease (AECOPD), it has a 30–40% failure rate when delivered using pressure support ventilation (PSV). Adaptive support ventilation with IntelliSync (ASVi) synchronizes breath initiation and cycling to match patient's requirements. We conducted a feasibility study to inform design of a larger trial and compared NIV failure rates using PSV or ASVi in patients with AECOPD.</div></div><div><h3>Materials and methods</h3><div>We conducted a single-center, randomized controlled trial from December 2023 to April 2025 in subjects with AECOPD. Subjects were randomized (1:1) to receive NIV using PSV or ASVi. The primary outcome was NIV failure, defined as the need for airway intubation. Key secondary outcomes included the asynchrony index and 28-day all-cause mortality.</div></div><div><h3>Results</h3><div>We included 55 consecutive subjects with AECOPD (ASVi, n = 26; PSV, n = 29), with a mean age of 63 years. NIV failure occurred in15.4% (4/26) with ASVi versus 31% (9/29) with PSV, representing a 50% relative risk reduction (absolute difference 15.6%, 95% CI: −6.2%–37.5%, P = 0.17). Asynchrony index was similar between groups (22.6 ± 17.8 ASVi vs. 21.5 ± 16.7 PSV, P = 0.83). ASVi was associated with significantly greater patient comfort (P = 0.048) and shorter hospital stay (3.9 ± 2.9 vs 5.8 ± 4.0 days, P = 0.021).</div></div><div><h3>Conclusion</h3><div>This study demonstrates that ASVi is safe, feasible to implement, and associated with improved patient comfort and significantly reduced hospital stay in AECOPD. The observed 50% relative reduction in NIV failure rates, although not statistically significant, represents a clinically meaningful effect that warrants evaluation in a larger trial.</div></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"253 ","pages":"Article 108690"},"PeriodicalIF":3.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146106945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of chronic obstructive pulmonary disease on cardiovascular outcomes and mortality benefits of sodium glucose co-transporter inhibitors in heart failure patients: A systematic review and meta-analysis","authors":"Rohab Sohail ,&nbsp;Zaraq Ahmad Khan ,&nbsp;Ridda Khattak ,&nbsp;Prakhar Anand ,&nbsp;Vyom Patel ,&nbsp;Marcos Alberto ,&nbsp;Mark Georgy ,&nbsp;Karan Dhand ,&nbsp;Andrei Feldiorean ,&nbsp;Seemab Fatima ,&nbsp;Sana Murtaza ,&nbsp;Manjeet Singh ,&nbsp;Syed Nazeer Mehmood","doi":"10.1016/j.rmed.2026.108685","DOIUrl":"10.1016/j.rmed.2026.108685","url":null,"abstract":"<div><h3>Background</h3><div>By 2030, healthcare expenditures related to congestive heart failure (CHF) in the United States are projected to surpass $70 billion. Despite substantial advances in guideline-directed medical therapy, morbidity and mortality remain unacceptably high, particularly among patients with concomitant chronic obstructive pulmonary disease (COPD), a comorbidity reported in approximately 5%–41% of individuals with CHF. Although COPD is independently associated with worse CHF outcomes, its influence on the mortality benefit conferred by sodium–glucose cotransporter-2 (SGLT-2) inhibitors remains poorly defined.</div></div><div><h3>Objective</h3><div>To evaluate whether COPD alters the cardiovascular and mortality benefit of SGLT-2 inhibitors in CHF patients.</div></div><div><h3>Methods</h3><div>PubMed, Cochrane and Google Scholar were searched from inception to February 2025 to identify studies meeting inclusion criteria. Review Manager was employed to calculate results in the form of relative risk (RR) with 95% confidence interval.</div></div><div><h3>Results</h3><div>Our analysis of 15,058 patients (1725 (11%) COPD patients) showed that COPD was associated with significantly higher risks of composite outcomes (RR = 1.63; 95% CI: 1.49–1.79; p &lt; 0.00001), CV mortality (RR = 1.62; 95% CI: 1.39–1.88; p &lt; 0.0001), heart failure hospitalization (RR = 1.84; 95% CI: 1.40–2.40; p &lt; 0.00001), and all-cause mortality (RR = 1.59; 95% CI: 1.42–1.78; p &lt; 0.00001). Additionally, adverse outcomes were more frequent in COPD patients, including volume depletion (RR = 1.34; 95% CI: 1.25–1.51; p &lt; 0.00001), and adverse renal events (RR = 1.46, 95% CI: 1.17–1.82; P = 0.0007).</div></div><div><h3>Conclusion</h3><div>Our analysis indicates that heart failure (HF) patients with COPD may drive a somewhat attenuated benefit from SGLT-2 inhibitors, underscoring a clinical profile that merits careful consideration.</div></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"253 ","pages":"Article 108685"},"PeriodicalIF":3.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146126364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}